Effect of rosiglitazone on amyloid precursor protein processing and Aβ clearance in streptozotocin-induced rat model of Alzheimer’s disease

Document Type: Original Article

Authors

1 Department of Geriatrics, the Second Affiliated Hospital of the Harbin Medical University, Harbin 150081, China

2 Department of Neurology, Peking University Third Hospital, Beijing 100080, China

3 Department of Neurology, The Second Affiliated Hospital of the Harbin Medical University, Harbin 150081, China

Abstract

Objective(s): Increasing evidence suggests that Alzheimer’s disease (AD) is associated with diabetes. Rosiglitazone, a peroxisome proliferator-activated receptor γ (PPAR-γ) agonist and anti-diabetic agent, may improve symptoms of AD. However, the underlying therapeutic potential of it has not been fully elucidated.
Materials and Methods: Rats were divided into four groups: control group, sham operated group, Streptozotocin (STZ) group, rosiglitazone (RGZ) group. Particularly, the STZ-induced rat model was established by intracerebroventricular injection (3 mg/kg) on the first and third day. The water maze behavioral test was performed to evaluate spatial reference learning and memory of the rats. Aβ1-40 and Aβ1-42 levels were measured by ELISA method. To determine APP-derived fragment, BACE1 and Aβ degrading enzymes levels, such as NEP and IDE, as well as Aβ transportation protein level, such as LRP1, RAGE, Abca1 and APOE , which were analyzed by Western blot. Immunohistochemistry was used to observe the change of Aβ1-40 and Aβ1-42 in hippocampus.
Results: Chronic treatment with RGZ could reduce the Aβ level and improved spatial memory performance in STZ-induced rat model. However, RGZ modified the expression of specific transport proteins monitoring Aβ clearance, such as ATP-binding cassette transporter 1 (ABCA1), lipoprotein receptor-related protein 1 (LRP1), and the advanced glycation end product-specific receptor (RAGE) rather than change levels of Aβ degrading enzymes, such as IDE and NEP, nor affect APP processing. 
Conclusion: As a potential therapeutic strategy, rosiglitazone might exert anti-AD effect not by alteration of APP processing pathway and Aβ degradation directly, but through promotion of Aβ clearance indeed.

Keywords


1.Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer’s Disease. Curr Alzheimer Res 2015; 12:32-46.

2.Koldamova R, Fitz NF, Lefterov I. ATP-binding cassette transporter A1: from metabolism to neurodegeneration. Neurobiol Dis 2014; 72:13-21.

3.Do TM, Dodacki A, Alata W, Calon F, Nicolic S, Scherrmann JM, et al. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD). J Alzheimers Dis 2015; 49:287-300.

4.Pahnke J, Langer O, Krohn M. Alzheimer's and ABC transporters--new opportunities for diagnostics and treatment. Neurobiol Dis 2014; 72:54-60.

5.Kanekiyo T, Liu CC, Shinohara M, Li J, Bu G. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimers amyloid-β. J Neurosci 2012; 32:16458-16465.

6.Provias J, Jeynes B. The role of the blood-brain barrier in the pathogenesis of senile plaques in Alzheimer's disease. Int J Alzheimers Dis 2014; 2014:191863.

7.Wang H, Chen F, Zhong KL, Tang SS, Hu M, Long Y, et al. PPARγ agonists regulate bidirectional transport of amyloid-β across the blood-brain barrier and hippocampus plasticity in db/db mice. Br J Pharmacol 2016; 173:372-385.

8.Cai Z, Liu N, Wang C, Qin B, Zhou Y, Xiao M, et al. Role of RAGE in Alzheimer's Disease. Cell Mol Neurobiol 2016; 36:483-495.

9.Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimers disease. J Clin Invest 2012; 122:1377-1392.

10.Chakrabarti S, Khemka VK, Banerjee A, Chatterjee G, Ganguly A, Biswas A. Metabolic risk factors of sporadic Alzheimer's disease: implications in the pathology, pathogenesis and treatment. Aging Dis 2015; 6:282-299.

11.Park SJ, Kim YH, Nam GH, Choe SH, Lee SR, Kim SU, et al. Quantitative expression analysis of APP pathway and tau phosphorylation-related genes in the ICV STZ-induced non-human primate model of sporadic Alzheimer’s disease. Int J Mol Sci 2015; 16:2386-2402.

12.Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J Am Geriatr Soc 2012; 60:916-921.

13.Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. Ann Neurol 2015; 78:284-294.

14.Cheng H, Shang Y, Jiang L, Shi TL, Wang L. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis. Int J Neurosci 2016; 126:299-307.

15.Ma L, Shao Z, Wang R, Zhao Z, Dong W, Zhang J, et al. Rosiglitazone improves learning and memory ability in rats with type 2 diabetes through the insulin signaling pathway. Am J Med Sci 2015; 350:121-128.

16.Xu S, Guan Q, Wang C, Wei X, Chen X, Zheng B, et al. Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses. Neurosci Lett 2014; 578:7-11.

17.Xu BL, Wang R, Meng XH, Zhao ZW, Wang HJ, Ma LN, et al. Effects of analog P165 of amyloid precursor protein 5-mer peptide on learning, memory and brain insulin receptors in the rat model of cognitive decline. Neurol Sci 2014; 35:1821-1826.

18.Kraska A, Santin MD, Dorieux O, Joseph- Mathurin N, Bourrin E, Petit F, et al. In vivo cross- sectional characterizationof cerebral alterations induced by intracerebro–ventricular  administration of streptozotocin. PloS One 2012;7:e46196.

19.Zhou L, Chen T, Li G, Wu C, Wang C, Sha S, et al. Activation of PPARγ ameliorates spatial cognitive deficits through restoring expression of AMPA receptors in seipin knock-out mice. J Neurosci. 2016; 36:1242-1253.

20.Pedersen WA, Mcmillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006; 199:265-273.

21.Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, et al. Neurons regulate extra cellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000; 20:1657-1665.

22.Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, et al. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci 2009; 29:1977-1986.

23.Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008; 58:681-693.

24.Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008; 118:671-682.

25.Shinohara M, Sato N, Kurinami H, Takeuchi D, Takeda S, Shimamura M, et al. Reduction of brain β-amyloid (Aβ) by fluvastatin, a hydroxymethyglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Aβ clearance. J Biol Chem 2010; 285:22091-22102.

26. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 2015; 11:457-470.